Roche’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease aft...
Phase III KATHERINE study shows Kadcyla significantly improved invasive disease-free survival compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.
Data will be submitted to health authorities around the world, including the US Food and Drug Administration and European Medicines Agency
Results will be presented at the 2018 San Antonio Breast Cancer Symposium in December.
Full details: https://www.roche.com/media/releases/med-cor-2018-10-15.htm?utm_source=T&utm_medium=E
Data will be submitted to health authorities around the world, including the US Food and Drug Administration and European Medicines Agency
Results will be presented at the 2018 San Antonio Breast Cancer Symposium in December.
Full details: https://www.roche.com/media/releases/med-cor-2018-10-15.htm?utm_source=T&utm_medium=E